RxDoctor Payments Data

Aileen Santos-Arroyo, MD

Dermatology · San Juan, PRNPI 1578821484

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,323 of the $2,630 with a category attached, or 88.3%. 11 manufacturers reported payments, led by AbbVie at 34.4% of the total. 2025 is the largest year on record at $963, 2.2 times the $443 reported in 2019.

$2,630in general payments, 2019–2025

Across 56 payments — averaging $46.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$905
  • Revance Therapeutics, Inc.$718
  • Johnson & Johnson$368
  • Sanofi$245
  • Galderma Laboratories, L.p.$166
  • PBG Puerto Rico LLC$82
  • plus $146 from 5 others

What the payments were for

  • Food & beverage$2,32388%
  • Education$30712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,630 in reported general payments places this provider in the 60th percentile of 108 dermatology providers in Puerto Rico.

See all dermatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$41,014
Medicare patients
131
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab35$257,122
Taltz AutoinjectorIxekizumab34$256,890
HumiraAdalimumab11$76,995
Mometasone Furoate717$20,114
Ammonium Lactate606$19,618
Ketoconazole644$13,456
Clobetasol Propionate185$12,554
Metronidazole222$12,423
Ciclopirox302$8,792
Desonide173$8,489
Triamcinolone Acetonide421$8,057
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc91$6,136
Betamethasone Dipropionate125$4,812
Calcipotriene19$4,498
Betamethasone Valerate118$4,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$905$76,99511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 108 dermatology providers in Puerto Rico.

Other dermatology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →